NovoCure Limited (NVCR)

Market Cap	2.04B
Revenue (ttm)	621.71M
Net Income (ttm)	-164.19M
Shares Out	111.49M
EPS (ttm)	-1.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	723,613
Open	18.32
Previous Close	18.31
Day's Range	17.68 - 18.53
52-Week Range	12.17 - 34.13
Beta	0.65
Analysts	Buy
Price Target	32.83 (+79.5%)
Earnings Date	Apr 24, 2025

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was inc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,488
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR
• Website: https://www.novocure.com

Financial Performance

In 2024, NovoCure's revenue was $605.22 million, an increase of 18.82% compared to the previous year's $509.34 million. Losses were -$168.63 million, -18.55% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $32.83, which is an increase of 79.50% from the latest price.

Price Target

$32.83

(79.50% upside)

Analyst Consensus: Buy